Anaemia is an independent predictor of poor outcome in patients with chronic heart failure

被引:109
作者
Szachniewicz, J
Petruk-Kowalczyk, J
Majda, J
Kaczmarek, A
Reczuch, K
Kalra, PR
Piepoli, MF
Anker, SD
Banasiak, W
Ponikowski, P
机构
[1] Mil Hosp, Dept Cardiol, PL-50891 Wroclaw, Poland
[2] Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, Dept Clin Cardiol, London SW7 2AZ, England
[3] Max Delbruck Ctr Mol Med, Franz Volhard Klin, Charite, Berlin, Germany
关键词
haemoglobin; anaemia; chronic heart failure; mortality;
D O I
10.1016/S0167-5273(02)00574-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Mild anaemia frequently occurs in patients with chronic heart failure (CHF), particularly in the advanced stages of the disease. The correction of anaemia with erythropoietin is a therapeutic possibility. The aim of this study was to assess prospectively the relationship between the prevalence of anaemia (haemoglobin levelless than or equal to120 g/l) and prognosis in an unselected CHF population. Methods: All consecutive patients with a diagnosis of CHF admitted to our department between January 2000 and April 2000 were considered for the present study. Those with secondary causes of anaemia were excluded. Patients were followed up until November 2001 (> 18 months in all survivors), and the end-point of the study was all-cause mortality. Results: A total of 176 patients were enrolled (mean age: 63 years, New York Heart Association (NYHA) classification I/II/III/IV: 15/81/51/29; left ventricular ejection fraction (LVEF): 42%, ischaemic aetiology in 62%). In the whole population the mean haemoglobin level was 140+/-15 g/l. Anaemia was found in 18 (10%) patients, and was significantly more common in women than in men (18 vs. 7%, respectively, P=0.02) and in those with most severe CHF symptoms (frequency in NYHA I/II/III/IV: 0/9/10/21%, respectively; NYHA IV vs. I-III, P=0.03), but not related to the other clinical indices. Univariate analysis revealed NYHA class III-IV (hazard ratio 3.8, 95% CI: 1.6-8.9, P=0.003), low LVEF <35% (hazard ratio 2.3, 95% CI: 1.0-4.9, P=0.04) and anaemia (hazard ratio 2.9, 95% CI: 1.2-7.2, P=0.02) as predictors of 18-month mortality. In multivariate analysis, anaemia remained an independent predictor of death when adjusted for NYHA class and LVEF (hazard ratio: 2.6, 95% CI: 1.0-6.5, P=0.04). In anaemic patients, 18-month survival was 67% (95% CI: 45- 89%) compared to 87% (81-92%) in patients with a normal haemoglobin level (P=0.016). Conclusions: Mild anaemia is a significant and independent predictor of poor outcome in unselected patients with CHF. Correction of low haemoglobin level may become an interesting therapeutic option for CHF patients. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:303 / 308
页数:6
相关论文
共 24 条
[1]   Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction [J].
Al-Ahmad, A ;
Rand, WM ;
Manjunath, G ;
Konstam, MA ;
Salem, DN ;
Levey, AS ;
Sarnak, MJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 38 (04) :955-962
[2]   Congestive heart failure hospitalizations and survival in California: Patterns according to race ethnicity [J].
Alexander, M ;
Grumbach, K ;
Remy, L ;
Rowell, R ;
Massie, BM .
AMERICAN HEART JOURNAL, 1999, 137 (05) :919-927
[3]   Wasting as independent risk factor for mortality in chronic heart failure [J].
Anker, SD ;
Ponikowski, P ;
Varney, S ;
Chua, TP ;
Clark, AL ;
WebbPeploe, KM ;
Harrington, D ;
Kox, WJ ;
PooleWilson, PA ;
Coats, AJS .
LANCET, 1997, 349 (9058) :1050-1053
[4]   The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin [J].
Besarab, A ;
Bolton, WK ;
Browne, JK ;
Egrie, JC ;
Nissenson, AR ;
Okamoto, DM ;
Schwab, SJ ;
Goodkin, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) :584-590
[5]   Serum erythropoietin in heart failure patients treated with ACE-inhibitors or AT1 antagonists [J].
Chatterjee, B ;
Nydegger, UE ;
Mohacsi, P .
EUROPEAN JOURNAL OF HEART FAILURE, 2000, 2 (04) :393-398
[6]   The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease [J].
Foley, RN ;
Parfrey, PS ;
Harnett, JD ;
Kent, GM ;
Murray, DC ;
Barre, PE .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1996, 28 (01) :53-61
[7]   HEMATOCRIT AND THE RISK OF CARDIOVASCULAR-DISEASE - THE FRAMINGHAM-STUDY - A 34-YEAR FOLLOW-UP [J].
GAGNON, DR ;
ZHANG, TJ ;
BRAND, FN ;
KANNEL, WB .
AMERICAN HEART JOURNAL, 1994, 127 (03) :674-682
[8]   CHANGES IN LEFT-VENTRICULAR SIZE, WALL THICKNESS, AND FUNCTION IN ANEMIC PATIENTS TREATED WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN [J].
GOLDBERG, N ;
LUNDIN, AP ;
DELANO, B ;
FRIEDMAN, EA ;
STEIN, RA .
AMERICAN HEART JOURNAL, 1992, 124 (02) :424-427
[9]   THE ERYTHROCYTE SEDIMENTATION-RATE IN CONGESTIVE-HEART-FAILURE [J].
HABER, HL ;
LEAVY, JA ;
KESSLER, PD ;
KUKIN, ML ;
GOTTLIEB, SS ;
PACKER, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (06) :353-358
[10]  
HERRLIN B, 1991, BRIT HEART J, V66, P199